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ABSTRACT
This manuscript discloses end-of-study safety data of a community-randomized controlled trial in Finland
(NCT00534638), assessing the effectiveness of two vaccination strategies (gender-neutral versus females
only) using the AS04-adjuvanted human papillomavirus (HPV)-16/18 (AS04-HPV-16/18) vaccine. The total
vaccination cohort included 32,175 adolescents aged 12–15 y at vaccination of whom 14,837 received the
AS04-HPV-16/18 vaccine and 17,338 received the hepatitis-B virus vaccine (control). Spontaneous report-
ing of serious adverse events (SAEs) combined with surveillance using nation-wide health registries
showed an acceptable safety profile of the AS04-HPV-16/18 vaccine. During the study period (up to 6.5
y), the incidences (per 100,000 person-years) of reported SAEs considered as possibly related to vaccina-
tion were 39.1 (95% confidence interval [CI]: 25.3–57.7) and 39.8 (95%CI: 26.8–56.8) in the HPV and control
groups, respectively. The most frequently reported new-onset autoimmune diseases (NOADs) were
ulcerative colitis (incidence rates of 28.2 and 33.1 per 100,000 person-years in the HPV and control groups,
respectively), insulin-dependent diabetes mellitus (21.9 and 37.1), Crohn’s disease (15.6 and 22.5), celiac
disease (15.6 and 21.2), and juvenile idiopathic arthritis (14.1 and 15.9). Of 1,344 pregnancies reported (777
and 567 in the HPV and control groups, respectively), most resulted in elective termination (58.4% and
58.6%), birth of a live infant (32.7% and 32.3%), or in spontaneous abortion (8.0% and 7.9%). No major,
registered congenital anomalies were identified. The incidence rates of NOADs and pregnancy outcomes
were generally balanced between groups. No specific safety signals were identified in the population-
based health registry surveillance.
Plain Language Summary
What is the context?
● Since first licensure in 2007 of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine
(Cervarix, GSK), large quantity of safety data has been collected and confirmed its safety profile.
This study provides further unique, population-based safety data from vaccinated Finnish
adolescents monitored via health registries up to 6.5 y of follow-up.
What is new?
● The vaccine has shown an acceptable safety profile in girls and boys. The risk of new-onset
autoimmune diseases (NOADs) was similar between the HPV vaccine group and the control
group and in line with the expectations for the studied population.
● The study supports that safety surveillance via national health registries is in general more sensitive
than the conventional safety reporting, notably for monitoring specific chronic diseases, e.g.
autoimmune disorders.
What is the impact?
● This study highlights the importance of health registries in long-term vaccination safety surveil-
lance. The population-based safety data reported in this study further support the routine admin-
istration of the HPV vaccine to girls and boys.
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Introduction
Since the first licensure in 2007, more than 71 million doses of
the prophylactic AS04-adjuvanted human papillomavirus
(HPV)-16 and −18 (AS04-HPV-16/18) vaccine have been
distributed worldwide.1 The vaccine was adjuvanted with an
adjuvant system (AS04) containing 3-O-desacyl-4ʹ-
monophosphoryl lipid A (50 μg MPL; produced by GSK)
adsorbed on aluminum salt (500 μg Al3+) and has
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demonstrated a strong and long-term efficacy against HPV
types 16 and 18, and a degree of cross-protection against the
types HPV-31, −33 and −45 phylogenetically related to HPV-
16 and −18, and potentially other types.2-5 The use of the
AS04 adjuvant initially raised theoretical safety concerns that
were not confirmed by the large quantity of data collected
from clinical trials and post-marketing surveillance which
have shown an acceptable safety profile of the AS04-HPV
-16/18 vaccine.6
The present phase III/IV controlled, randomized study
(ClinicalTrials.gov NCT00534638) was designed to evaluate
the effectiveness of two vaccination strategies (gender-
neutral versus females only) using the AS04-HPV-16/18 vac-
cine in reducing the prevalence of HPV-16/18 infection in
young women when administered in adolescents in Finland.
As an important secondary objective, new-onset autoimmune
diseases (NOADs) and pregnancy outcomes were monitored
in the study via nation-wide health registries which are part of
the public health infrastructure in Nordic countries. Interim
safety results of the trial reported in 2016 showed an accep-
table safety profile of the AS04-HPV-16/18 vaccine in girls
and boys.7 This article reports the final safety outcomes from
this population-based cluster-randomized trial.
Materials and methods
Methods of the study were previously detailed and
published.7,8
Study design
Between October 2007 and April 2010, 80,272 Finnish male
and female adolescents, born between 1992 and 1995 from 33
communities were invited to participate in this study and
randomized into three arms.7
In Arm A communities, boys and girls were randomly
assigned to receive either the AS04-HPV-16/18 vaccine
(Cervarix, GSK; 90% of the vaccinated subjects) or the hepa-
titis B virus (HBV) vaccine (Engerix B, GSK; 10% of the
vaccinated subjects). This vaccine was chosen as control vac-
cine given its well-known and acceptable safety profile and the
benefit that it would confer to the subjects unvaccinated with
it at the time of the enrollment. In Arm B communities, girls
were randomly assigned to receive either the AS04-HPV-16/
18 vaccine (90% of the vaccinated subjects) or the HBV
vaccine (10% of the vaccinated subjects). All the remaining
vaccinated subjects (i.e. 10% of boys and girls in Arm A, 10%
of girls and all boys in Arm B, and all participants in Arm
C communities) were assigned to receive the HBV vaccine.
Vaccine doses were administered at Months 0, 1 and 6 at
schools by the same study nurses. To limit bias for analysis,
blinding was maintained for all subjects in Arm A and for
girls in Arm B.
The study was approved by the ethics committee of the
Pirkanmaa hospital district and conducted in accordance with
the Declaration of Helsinki, good clinical practice and all
applicable regulatory requirements. Written informed assent
was provided by subjects younger than 15 y while written
informed consent was obtained from those aged ≥15 y and
from participants’ parents or legal representatives prior to the
initiation of any study-specific procedures.
Safety reporting
Three methods were applied in the study for safety surveil-
lance according to gender and intervention arm: active sur-
veillance, registry-based surveillance and spontaneous
reporting.
Active safety surveillance was performed from Month 0 to
Month 12 in all males from Arm A communities and in males
from Arm C communities included in the Diary Card subset
and who were actively questioned by the investigator at each
visit about any serious adverse events (SAE) that occurred until
Month 12 after the first vaccine dose. These subjects were asked
to record solicited local and general symptoms within 7 days (D
0–6) and unsolicited AEs within 30 days (D 0–29) after each
vaccine dose. These subjects were also actively questioned at
Months 7 and 12 about any medically significant conditions
including NOADs and SAEs that might have occurred after the
first vaccination. Active safety surveillance for the occurrence
of SAEs was also performed in boys from Arm A communities
who were not included in the diary card subset at Months 7 and
12.7 All SAEs reported to the investigator and considered
possibly related to vaccination were reported using a remote
data entry system at the study sites.
Registry-based safety surveillance was performed for all
study participants in all intervention arms during the entire
study period up to visit 5 (within ± 1.5 months of reaching 18.5
y). For the Care Register for Social Welfare and Health Care
(HILMO)-based analysis, consent was given by study partici-
pants for personal identity code (PIC)-based linkages of the
Registry of Vaccinated Individuals (RVI) and the HILMO. The
RVI and HILMO registry linkage for predefined NOADs was
performed after the HILMO had been completed for the
International Classification of Diseases-10 (ICD-10) diagnoses
made by Finnish healthcare.9 The cases identified in the register
linkage were confirmed by medical history data obtained from
the hospitals and hospital municipal health centers, which were
reviewed by the principal investigator. Time of onset within 18
months from the first vaccine dose (i.e. approximately 12
months from the last vaccine dose) was the time window
used for temporal association, and considered by the investi-
gator to not exclude a possible causality. Indeed, Regulatory
Authorities have previously recommended a safety follow-up
period of 6–12 months post-vaccination for immune-mediated
diseases for all vaccines formulated with novel adjuvants. It is
considered that autoimmunity occurrence linked to a vaccine is
less likely to occur after 6–12 months following
vaccination.10,11 For the NOAD causality assessment, the inves-
tigator was blinded to both vaccination and community status,
that could have indirectly disclosed the vaccination status.
Safety surveillance also included spontaneous reporting of
pregnancies as well as pregnancies retrieved from the Medical
Birth Registry and HILMO databases in all female study
participants. The Medical Birth registry included sub-
registers such as the Medical Birth Register and Abortion
Register, which were used in data retrieval.
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Statistical analyses
Statistical analyses were performed on the Total Vaccinated
Cohort, and were purely descriptive. The analysis of safety
data was performed by treatment groups: study participants
who received the AS04-HPV-16/18 vaccine and study partici-
pants who received the HBV vaccine.
The number of withdrawn subjects was tabulated accord-
ing to the reason for withdrawal. The mean, median, range
and standard deviation of age in years at Dose 1 and at Visit 5
of the study participants were calculated by gender and vac-
cine group. Other demographic characteristics (i.e. birth
cohort, area type, ethnicity, and geographic ancestry) were
tabulated. The incidence rates (per 100,000 person-years) of
subjects experiencing at least one SAE judged possibly related
to vaccination according to the investigator and classified by
the Medical Dictionary for Regulatory Activities (MedDRA)
during the entire follow-up period were calculated by vaccine
group for all participants and by gender (self-identified) with
exact 95% confidence interval (CI), together with relative risk
(RR) adjusted by gender (and 95% CI).
The incidence rates (per 100,000 person-years) of subjects
reporting at least one NOAD classified by MedDRA during the
entire follow-up period were calculated with exact 95% CI,
together with RR adjusted by gender (and 95% CI). NOADs
reported as possibly related to vaccination and serious NOADs
were tabulated similarly. Pregnancies and pregnancy outcomes
over the total number of pregnancies reported during the entire
study period were tabulated by vaccine group and overall.
Results
Study population
Between October 2007 and December 2014, 32,175 Finnish
adolescents (20,512 girls and 11,663 boys) from 33 commu-
nities were enrolled and received at least one dose of study
vaccines (Figure 1). Overall, the AS04-HPV-16/18 vaccine was
administered to 14,837 adolescents (12,401 girls and 2,436
boys) and the control HBV vaccine to 17,338 adolescents
(8,111 girls and 9,227 boys). Almost all (99.4%) participants
received all three doses and most were of Caucasian/European
heritage (99.1%) (Table 1).
SAEs considered as possibly related to vaccination
During the follow-up period up to 6.5 y, the observed inci-
dence rates (per 100,000 person-years) for SAEs considered as
possibly related to vaccination according to investigators’
assessment were 39.1 (95% CI: 25.3–57.7) in the AS04-HPV
-16/18 vaccine group and 39.8 (95% CI: 26.8–56.8) in the
HBV vaccine group. Considering SAEs possibly related to
vaccination (with incidence rates ≥5 per 100,000 person-
years in at least one group), the most common were ulcerative
colitis in the AS04-HPV-16/18 vaccine group (7.8 per
100,000 person-years in the AS04-HPV-16/18 vaccine group
vs. 4.0 per 100,000 person-years in the HBV vaccine group)
and insulin-dependent diabetes mellitus (IDDM) in the HBV
vaccine group (4.7 per 100,000 person-years in AS04-HPV
Figure 1. Subject disposition.
aSubjects with registry-based follow-up during the entire study period regardless of their completion of the study. bVisit 5 (within ± 1.5 months of reaching 18.5 y).
AS04-HPV-16/18: AS04-adjuvanted HPV-16/18 vaccine; HBV: hepatitis-B virus vaccine; N: number of subjects.
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-16/18 vaccine group vs. 11.9 per 100,000 person-years in the
HBV vaccine group) (Table 2). No fatal SAEs considered
possibly related to vaccination were reported. Incidence rates
by gender are presented in supplementary Tables 1 and 2.
New-onset auto-immune diseases in all study participants
The overall incidence rates of NOADs were similar in both
vaccine groups: 233.1 per 100,000 person-years in the AS04-
HPV-16/18 vaccine group and 238.5 per 100,000 person-years
in the HBV vaccine group.
During the entire study period, in all study participants,
the most common NOADs (with incidence rates ≥ 15 per
100,000 person-years in any group) were ulcerative colitis
(incidence rates of 28.2 and 33.1 per 100,000 person-years in
the AS04-HPV-16/18 vaccine and HBV vaccine groups,
respectively), IDDM (incidence rates of 21.9 and 37.1 per
100,000 person-years, respectively), Crohn’s disease (inci-
dence rates of 15.6 and 22.5 per 100,000 person-years, respec-
tively), celiac disease (incidence rates of 15.6 and 21.2 per
100,000 person-years, respectively), and juvenile idiopathic
arthritis (incidence rates of 14.1 and 15.9 per 100,000 person-
years, respectively) (Table 2). Incidence rates by gender are
presented in supplementary Tables 1 and 2.
The 95% CIs of RR estimates for the incidence of NOADs in
the AS04-HPV-16/18 vaccine group as compared to the HBV
vaccine group are presented in Figure 2. The observed RR
(adjusted for gender) for IDDM was 0.72 (95% CI: 0.33–1.52)
in the overall population, 0.65 in females (95% CI: 0.24–1.75),
and 0.85 in males (95% CI: 0.21–2.58). All 95% CIs of RR
estimates included 1.
Overall, incidence rates for serious NOADs were also simi-
lar between groups; 76.6 (95% CI 56.7–101.3) and 94.1 (95%
CI 73.5–118.7) per 100,000 person-years for the AS04-HPV
-16/18 and HBV vaccine groups, respectively. The most com-
mon serious NOADs in all study participants (≥10 per
100,000 person-years) were ulcerative colitis (incidence rates
of 18.8 and 18.6 per 100,000 person-years in the AS04-HPV
-16/18 and HBV vaccine groups, respectively), Crohn’s dis-
ease (incidence rates of 10.9 and 19.9 per 100,000 person-
years, respectively), and IDDM (incidence rates of 20.3 and
33.1 per 100,000 person-years, respectively).
For NOADs that were possibly causally related to vaccina-
tion according to investigator assessment, no new cases were
reported since the previous results disclosed in the interim
analysis.3 The most common NOADs possibly related to
vaccination (≥ 10 per 100,000 person-years) in all study par-
ticipants were celiac disease (incidence rates of 7.8 and
10.6 per 100,000 person-years in the AS04-HPV-16/18 and
HBV vaccine groups, respectively), IDDM (incidence rates of
6.3 and 13.3 per 100,000 person-years, respectively), and
juvenile idiopathic arthritis (incidence rates of 10.9 and
9.3 per 100,000 person-years, respectively).
Pregnancies in all female study participants
During the entire study, a total of 1,344 pregnancies were
reported (777 in girls receiving the AS04-HPV-16/18 vac-
cine and 567 in girls receiving the HBV vaccine) at the
time of the final analysis. Most of the pregnancies resulted
in elective termination with no major, registered congeni-
tal anomaly (58.4% in the AS04-HPV-16/18 vaccine group
and 58.6% in the HBV vaccine group) or birth of a live
infant with no major, registered congenital anomaly
(32.7% and 32.3%, respectively). The other pregnancy out-
comes were spontaneous abortion with no major, regis-
tered congenital anomaly (8.0% in the AS04-HPV-16/18
vaccine group and 7.9% in the HBV vaccine group), ecto-
pic pregnancy (0.6% and 0.9%, respectively), molar preg-
nancy (0.3% and 0.2%) and stillbirth with no major,
registered congenital anomaly (one case in HBV vaccine
group [0.2%]).
Discussion
This large cluster-randomized post-marketing cohort study
provides a significant amount of unique health registry-
based safety data of the AS04-HPV-16/18 vaccine comparing
with a routinely used HBV vaccine up to 6.5 y of follow-up in
young adolescents recruited in a population-based fashion.
Population-based health registries using online linkage sys-
tems are important sources for quantitative real-world data
analysis in safety surveillance of population-based vaccination
trials and programs and are of more and more interest to
health authorities. As one of the most important health reg-
isters in Finland, HILMO gathers electronic medical records
from discharge information of all hospitals and care periods
in social care institutions and is widely used for scientific
research.9 Several studies that assessed the reports of
HILMO in different therapeutic areas concluded to its relia-
bility and the validity of the data collected.12-14
Given longstanding theoretical concerns of an association
between vaccines and autoimmune disorders, the follow-up of
NOADs is important to ensure confidence in immunization
programs. This is more relevant to HPV vaccines which are
mostly used in young women who may be more prone to
develop autoimmune diseases due to hormonal and genetic
factors.15 At its launch, the AS04-HPV-16/18 vaccine raised
a similar theoretical concern of inducing or exacerbating poten-
tial immune-mediated diseases due to the use of a novel adju-
vant. The safety of the vaccine has been monitored through the
standardized methodology for the collection of AEs of special
interest (AESI) in the 13 y post-marketing surveillance. Data
collected and analyzed do not support a link between the
vaccine and autoimmune disorders10,16-18 and the benefit–risk
balance of the AS04-HPV-16/18 vaccine remains favorable.
Long-term prospective registry-based safety follow-up in this
cluster-randomized trial showed that the incidence rates of
NOADs were generally balanced (all 95% CI of the RR estimates
included 1) between subjects who received the AS04-HPV-16/18
vaccine and those who received an HBV vaccine. For many of
the potential autoimmune disorders searched in HILMO with
pre-defined ICD-10 codes, only few medical record-confirmed
NOADs were found in either vaccine group. During the entire
follow-up period of the study (from 3.5 to 6.5 y for individual
subjects who joined the study at the ages of 12–15 y), the most
commonly reported NOADs were inflammatory bowel diseases
(IBD) (ulcerative colitis and Crohn’s disease) and IDDM. More
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cases of IBD were reported after the interim analysis (with
approximately 1–3 y more follow-up time for all subjects until
they reached the age of 19 y),3 which can be explained by the fact
that although IBD can occur at any age, it is more frequently
diagnosed between the ages of 15 and 35 y.19
The interim analysis7 showed a lower incidence of IDDM
in AS04-HPV-16/18 vaccinees (8.3 per 100,000 person-years)
compared to HBV vaccinees (50.7 per 100,000 person-years),
and to the reported incidence in somewhat younger, 10- to
14-year-old Finns (50.4 per 100,000 person-years).20 The
interim results suggested that HPV vaccination might lower
the risk of IDDM7 but this finding was however not con-
firmed in the end-of-study analysis (RR of 0.72 [95% CI:
0.33–1.52]).
No safety concerns on autoimmunity were identified in
this study for both girls and boys. The frequency of NOADs
is in line with the expectations for this population.21 These
findings are consistent with data provided by several studies,
including a recent 3-year follow-up register-based cohort
study in Finland and an observational 1-year follow-up cohort
study in the UK where no evidence of an increased risk of
NOADs following AS04-HPV-16/18 vaccination was observed
in girls aged 11–15 y or in women aged 9–25 y,
respectively.22,23
The strengths and limitations of the study were described
in detail in the previous paper which disclosed interim data.7
One more possible limitation may link to the codes and
classification of diagnoses in the registry. Despite the recog-
nized completeness and accuracy in the registry, and the high
positive predictive value (PPV) for common diagnoses13 reg-
istry data may have the potential to have low PPV for rare
outcomes such as certain autoimmune disorders. Overall this
study showed post-marketing safety surveillance via national
health registries was more sensitive than the conventional
SAE surveillance, especially for monitoring specific chronic
diseases and pregnancy outcomes. Appropriate design, espe-
cially population-based recruitment and health registry fol-
low-up, are essential in this type of research to help identify
signals for further investigation.
Conclusions
No new safety concerns were identified in the final safety
analysis (up to 6.5 y follow-up) of this population-based
Figure 2. Estimated relative risk of the occurrence of NOADs in the AS04-HPV-16/18 vaccine group compared to the HBV vaccine group adjusted for gender with 95%
confidence interval (Total Vaccinated Cohort).
NOADs were classified by Medical Dictionary for Regulatory Activities (MedDRA) primary system organ class and preferred term, during the entire study period (all
study participants, Total Vaccinated Cohort). Dots represent point estimates. The following NOADs which occurred only in the AS04-HPV-16/18 vaccine group are not
shown in one subject for Erythema multiforme, Dermatitis psoriasiform, Tubulointerstitial nephritis and uveitis syndrome, Multiple sclerosis relapse, Mononeuritis,
Scleroderma, Sarcoidosis, Cholangitis sclerosing, Iridocyclitis and Thyroiditis; 2 subjects for Raynaud’s phenomenon. The following NOADs which occurred only in the
HBV vaccine group are not shown in one subject for Encephalitis, Spondylitis, Guillain–Barre syndrome, Iga nephropathy, and Stevens–Johnson syndrome; two
subjects for Sjorgen’s syndrome; three subjects for Lichen planus.AS04-HPV-16/18: AS04-adjuvanted HPV-16/18 vaccine; CI: confidence interval; HBV: hepatitis-B virus
vaccine; NOADs: new-onset autoimmune diseases.
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cluster-randomized trial. This conclusion is based on the
comparison of the AS04-HPV-16/18 vaccine with the HBV
vaccine, the latter demonstrating a well-known and acceptable
safety profile. This study further highlights the importance of
health registries in long-term post-vaccination safety surveil-
lance. The favorable safety data reported in this nationwide
study support the routine administration of the AS04-HPV
-16/18 vaccine to girls and boys.
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